Rami Heart, DO
Interventional Cardiology · Panama City, FLNPI 1891020079
Payments from drug & device makers
Across 423 payments — averaging $39.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abiomed$4K
- Boston Scientific$2K
- Penumbra, Inc.$2K
- Cardiovascular Systems Inc.$2K
- Abbott$1K
- Shockwave Medical, Inc$1K
- plus $5K from 28 others
What the payments were for
- Travel & lodging$1,89011%
- Food & beverage$14,94989%
- Education$220%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abiomed | 123 | $4,267 |
| Boston Scientific | 41 | $2,020 |
| Penumbra, Inc. | 17 | $1,689 |
| Cardiovascular Systems Inc. | 41 | $1,558 |
| Abbott | 31 | $1,271 |
| Shockwave Medical, Inc | 18 | $1,156 |
| Biotronik Inc. | 12 | $778 |
| Inari Medical, Inc. | 14 | $606 |
| Cook Medical LLC | 5 | $591 |
| Stryker | 20 | $555 |
| Johnson & Johnson | 18 | $419 |
| Novartis | 16 | $280 |
| AstraZeneca | 14 | $222 |
| Merck | 9 | $193 |
| Medtronic(2 entities) | 4 | $184 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 8 | $156 |
| Venclose Inc. | 1 | $128 |
| Opsens Inc. | 1 | $100 |
| Endologix LLC | 1 | $86 |
| E.r. Squibb & Sons, L.L.C. | 5 | $84 |
| Lexicon Pharmaceuticals, Inc. | 4 | $80 |
| Bard Peripheral Vascular, Inc. | 1 | $79 |
| Amgen | 4 | $62 |
| Boehringer Ingelheim | 4 | $60 |
| Baxter Healthcare | 1 | $39 |
| Siemens Medical Solutions USA, Inc. | 1 | $38 |
| Novo Nordisk | 1 | $28 |
| Livanova USA, Inc. | 2 | $25 |
| Heartflow, Inc. | 1 | $22 |
| Philips North America LLC | 1 | $20 |
| Atricure, Inc. | 1 | $18 |
| Irhythm Technologies, Inc. | 1 | $18 |
| Cvrx, Inc. | 1 | $15 |
| Amarin Pharma, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Impella$1,390
- Indigo System$1,133
- Orsiro$617
- Astron; Pulsar; AstronPulsar$617
- PRO-Kinetic Energy$617
- Pulsar$617
- PK Papyrus$617
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$572
- GENERAL - THERAPIES$470
- Peripheral Orbital Atherectomy System$387
- Cook Medical Peripheral Intervention$340
- Vascular Lithotripsy$317
- FLOWTRIEVER CATHETER, S$298
- CT THROMBECTOMY SYSTEM KIT$298
- Coronary Orbital Atherectomy System$278
- GENERAL VASCULAR INTERVENTION$252
- Indigo$243
- XARELTO$210
- COROFLOW$163
- FlowTriever$156
How this compares
$16,862 in reported general payments places this provider in the 60th percentile of 623 interventional cardiology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 103 | $86,026 |
| XareltoRivaroxaban | 69 | $52,421 |
| EntrestoSacubitril/Valsartan | 49 | $51,058 |
| FarxigaDapagliflozin Propanediol | 42 | $26,738 |
| JardianceEmpagliflozin | 33 | $24,519 |
| BrilintaTicagrelor | 40 | $19,567 |
| Repatha SureclickEvolocumab | 22 | $15,575 |
| Metoprolol Succinate | 251 | $2,424 |
| Ranolazine ErRanolazine | 78 | $2,363 |
| Rosuvastatin Calcium | 279 | $2,243 |
| Nifedipine ErNifedipine | 111 | $2,141 |
| Potassium Chloride | 155 | $1,983 |
| ClopidogrelClopidogrel Bisulfate | 188 | $1,333 |
| Carvedilol | 214 | $1,197 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 37 | $963 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $419 | $52,42169 claims |
| NovartisEntresto | $280 | $51,05849 claims |
| AstraZenecaFarxiga, Brilinta | $222 | $46,30582 claims |
| Boehringer IngelheimJardiance | $60 | $24,51933 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 623 interventional cardiology providers in Florida.
Other interventional cardiology in Panama City
- Dominick AngiolilloJacksonville$4M
- Douglas SpriggsClearwater$3.2M
- Rakesh PrashadOcala$3.1M
- Aldo Martinez FleitesMiami Lakes$2.2M
- Rohit AminPensacola$2M
- Roberto CubedduNaples$2M
- Arthur LeeGainesville$2M
- Ruby SatpathyJacksonville$1.8M
- Santhosh MathewsBradenton$1.7M
- Pedro Martinez-ClarkMiami$1.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.